In this study, using the CKD Health Policy Model [6–9], we explored the most cost-effective Hb target for anemia treatment in persons with CKD stages 3–4, representing persons with estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2 not on dialysis. The gene discussed is GSTM1; the disease is anemia.